Cancer genomic profiling predicts pathogenicity of BRCA1 and BRCA2 variants
Olga Kondrashova(QIMR Berghofer Medical Research Institute), Nicola Waddell(QIMR Berghofer Medical Research Institute), Dexter X. Jin(Foundation Medicine (United States)), MELISSA CLINE(University of California, Santa Cruz), Khoa Tran(Queensland University of Technology), Michael T. Parsons, Garrett M. Frampton(Tech Foundation), Daffodil M. Canson(QIMR Berghofer Medical Research Institute), Rebecca L. Johnston(QIMR Berghofer Medical Research Institute), Brennan Decker(Foundation Medicine (United States)), Smruthy Sivakumar(Foundation Medicine (United States)), Amanda B Spurdle(QIMR Berghofer Medical Research Institute), Ethan S Sokol(Foundation Medicine (United States)), Aimee L. Davidson(QIMR Berghofer Medical Research Institute), Dean C Pavlick(Foundation Medicine (United States))
Cited by 0
Related Papers
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
|Genome Medicine|2017|3.7k
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
|Nature Immunology|2017|639
Genome-wide analysis of long noncoding RNA stability
|Genome Research|2012|592